E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
- leukemia
- leukemia,pediatric
- leukemia, myleiod
- leukemia, mylegenous, chronic
- leukemia, mylegenous, accelerated
- BCR-ABL positive
- myeloproliferative disorder
- bone marrow disease
- hematologic diseases
- neoplastic processes |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009012 |
E.1.2 | Term | Chronic myelogenous leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To assess efficacy of nilotinib in pediatric patients with Ph+ CML CP resistant or intolerant to either imatinib or dasatinib
2. To assess efficacy of nilotinib in pediatric patients with Ph+ CML AP resistant or intolerant to either imatinib or dasatinib
3. To assess efficacy of nilotinib in pediatric patients with newly diagnosed Ph+ CML CP |
|
E.2.2 | Secondary objectives of the trial |
1. To further characterize efficacy and PK profile of nilotinib in pediatric
patients with Ph+ CML
2. To further characterize safety and tolerability of nilotinib in pediatric
patients with Ph+ CML
3. To assess long term effect on growth, development and maturation of
nilotinib treatment in pediatric patients with Ph+ CML
4. To identify emerging signs of resistance to nilotinib
5. To describe acceptability of the study drug formulation |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients eligible for inclusion in this study have to meet all of the
following criteria:
1. Male or female patients from 1 year of age to less than 18 years of age
at study entry
2. Newly diagnosed Ph+ CML-CP or Ph+ CML-CP or AP resistant or
intolerant to either imatinib or dasatinib (as defined in the protocol)
3. Performance status: Karnofsky ≥50% for patients >10 years of age,
and Lansky ≥50 for patients ≤10 years of age.
4. Adequate renal, hepatic and pancreatic function as defined in the
protocol
5. Patients must have potassium, magnesium, phosphorus and total
calcium values ≥LLN (lower limit of normal) or corrected to within
normal limits with supplements prior to the first dose of study
medication
6. Written informed consent prior to any screening procedures. However,
if requested tests were performed as part of clinical practice within the
window required per protocol, this data can be used provided all
parameters required per protocol were verified. |
|
E.4 | Principal exclusion criteria |
Patients eligible for this study must not meet any of the following
criteria:
1. Female patients who are : (a) pregnant, (b) of childbearing potential
without a negative hCG pregnancy test prior to baseline and (c) female
of childbearing potential who do not agree to abstinence or, if sexually
active, do not agree to the use of highly effective contraception
2. Patients actively receiving therapy with strong CYP3A4 inhibitors or
inducers and the treatment cannot be either discontinued or switched to
a different medication at least 14 days prior to starting study drug
3. Patients who are currently receiving treatment with any medications
that have a known risk or possible risk to prolong the QT interval and the
treatment cannot be either discontinued or switched to a different
medication prior to starting study drug.
4. Acute or chronic liver, pancreatic or severe renal disease considered
unrelated to CML
5. History of pancreatitis within 12 months of prior to starting study
drug or past medical history of chronic pancreatitis
6. Active or systemic bacterial, fungal, or viral infection as documented
by positive cultures, radiological imaging techniques, or septic shock
syndrome. Such infections should have been resolved for ≥2 weeks
before including the patient in the study
7. Impaired cardiac function as defined in the protocol
8. Patients with documented T315I mutation in BCR-ABL
9. Previous treatment with more than one TKI for imatinib or dasatinib
resistant/intolerant Ph+ CML patients. Previous treatment with any TKI
for newly diagnosed Ph+ CML patients is not permitted unless the
patient has received imatinib for less than 2 weeks prior to the first dose
of study drug and discontinued at least 5 days prior to the first dose of
nilotinib.
10. Patients who have received myelosuppressive chemotherapy less
thanwitinwithin 3 weeks, imatinib within 5 days, or dasatinib within 3
days prior to the first dose of study drug
11. Patients who have not recovered from all acute toxicities from all
prior myelosuppressive chemotherapy prior to starting study drug
12. Patients receiving hydroxyurea greater than 21 days for the
treatment of Ph+ CML either prior to initiation of nilotinib or with
maximum duration planned to exceed one week post initiation of
nilotinib
13. Patients who have received hematopoietic growth factors within 7
days prior to starting study drug
14. Patients who have received Pegfilgrastim (Neulasta®) within 14
days prior to starting study drug
15. In case of Stem Cell Transplant (SCT) or Rescue without total body
irradiation (TBI):
Evidence of either active graft vs. host disease or less than 3 months
since SCT.
16. In case of radiation therapy: less than 2 weeks if local palliative, less
than 3 months after total body irradiation (TBI), or craniospinal
radiation therapy or if at least 50% radiation of pelvis; less than 6 weeks
after other substantial BM radiation
17. Patients with known Hepatitis B, Hepatitis C, or HIV infection
18. Patients who, in the opinion of the investigator, are unlikely to
comply with the protocol or safety monitoring requirements
19. Patients who are breast feeding
20. Patients who have a known hypersensitivity to the active ingredient
or any of the excipients including lactose
21. Impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of study drug (e.g., ulcerative disease,
uncontrolled nausea, vomiting, diarrhea, mal-absorption, small bowel
resection, or gastric bypass surgery)
22. Severe and/or uncontrolled concurrent medical disease that in the
opinion of the investigator could cause unacceptable safety risks or
compromise compliance with the protocol (e.g., diabetes, infection,
febrile neutropenia etc.). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Rate of Major Cytogenetic Response (MCyR)
2. Rate of Complete Hematological Response (CHR)
3. Rate of Major Molecular Response (MMR)
4. Rate of Complete Cytogenetic Response |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. At 6 cycles
2. By 3 cycles
3. By 12 cycles
4. At 12 cycles |
|
E.5.2 | Secondary end point(s) |
1.Time to response, duration of response, time to disease progression,
overall survival, event free survival
2. Rate of MCyR and CCyR
3. Rate of MMR and CHR
4. Population Pharmacokinetic parameters of nilotinib
5. Pharmacodynamics (BCR-ABL transcript levels determined with
standard protocols in peripheral blood)
6. Safety and tolerability: incidence and severity of adverse events, as
assessed by patient symptoms, physical exam assessments, abnormal
laboratory tests, echocardiograms and electrocardiograms
7. Assessment of development (growth and sexual maturation), and
thyroid function
8. Mutational assessment of BCR-ABL
9.Questionnaire on acceptability (including palatability) of dose forms
used after first dose, cycle 1 and cycle 12 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Up to 66 cycles
2. By 6, 12, 18, 24, 36, 48, and 66 cycles
3. By 3, 6, 9, 12, 18, 24, 36, 48, and 66 cycles
4. Up to 12 cycles
5. Up to 66 cycles
6. Continuous
7. Up to 66 cycles
8. Up to 66 cycles
9. After 1st dose, cycle 1, and cycle 12
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
acceptability of study drug formulation (including palatability) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 33 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
France |
Germany |
Hungary |
Italy |
Japan |
Korea, Republic of |
Netherlands |
New Zealand |
Russian Federation |
Spain |
Thailand |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study is defined as the timepoint when all patients have
completed the Study Evaluation Completion (SEC) visit. The SEC will
either be a minimum of 30 days post Cycle 66 or a minimum of 30 days
post early discontinuation. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 3 |